Category: 151038-94-7

151038-94-7, 6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanehydrazide 2,2,2-trifluoroacetate is a pyrrolines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

151038-94-7, The synthesis of DOXO-EMCH was accomplished using the procedure reported by Willner et al, with several changes to improve the yield (Willner, D., et al.,Bioconjugate Chem., 4:521-27, 1993). DOX’HCl (20 mg, 34 muiotaetaomicron) was dissolved in 6 mL of methanol. Pyridine (12.53 mu) was added to the solution, followed by 35.4 mgEMCH’TFA. The reaction was stirred at room temperature overnight. By HPLC, the reaction was 90% complete. The solvent was evaporated to dryness by rotary evaporation. A minimal amount of methanol was used to dissolve the solid, and six volumes of acetonitrile at 4 C were added to the solution. The resulting solution was allowed to sit undisturbed at 4 C for 48 h for crystallization. The precipitate was collected, and the crystallization method was repeated 4 times. The resulting solids were combined and washed three times with 1 : 10 methanokacetonitrile. The final yield of DOXO-EMCH was 11.59 mg, 58%. HPLC Method 1.1 was used. NMR spectra corresponded to those previously given by Willner (Bioconjugate Chem. 4:521-27. 1993).

As the paragraph descriping shows that 151038-94-7 is playing an increasingly important role.

Reference£º
Patent; THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE; KOCH, Tad, H.; BARTHEL, Benjamin, L.; ROWAN, Alexander, R.H.; WO2012/167255; (2012); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.151038-94-7,6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanehydrazide 2,2,2-trifluoroacetate,as a common compound, the synthetic route is as follows.

EMCH-TFA (3 equiv) and 0.75 equiv TFA were added to an anhydrous ethanol (dried by 3 A molecular sieves, superactivated by heating to 150 C under a vacuum of 0.1 Torr) solution (8.57 mL) of PPD (15 mg, 18.3 muiotaetaomicron, 1 equiv) and stirred under a nitrogen atmosphere overnight at room temperature. The extent of the reaction was monitored by HPLC (Method 1.3). Once 90% complete by HPLC, the solution was evaporated to dryness and the residue redissolved in anhydrous DMSO. PPD/PPD-EMCH was precipitated by adding at least 3 volumes of PBS (pH 7.4). The precipitate was washed with dH20 (pH > 6.5) and redissolved in DMSO. The precipitation was repeated three times, followed by further purification by radial chromatography, eluting PPD and PPD-EMCH with 90: 1 and 20: 1 chloroform:methanol, repectively. NMR spectra were obtained at 56C in deuteriochloroform (Figure 5)., 151038-94-7

The synthetic route of 151038-94-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE; KOCH, Tad, H.; BARTHEL, Benjamin, L.; ROWAN, Alexander, R.H.; WO2012/167255; (2012); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.151038-94-7,6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanehydrazide 2,2,2-trifluoroacetate,as a common compound, the synthetic route is as follows.

Acetate 4-(l-(2-(6-(2,5-dioxo-2H-pyrrol-l(5H)- yl)hexanoyl)hydrazono)ethyl)benzoate oxaliplatin was synthesized using acetoxyoxalplatin(4-acetylphenyl)carboxylate (328 mg, 0.529 mmol, 1.00 equiv.) that was dissolved in DMF (0.05 M, 10 mL) and treated with 6-(2,5-dioxo-2,5-dihydro-lH- pyrrol-l-yl)hexanehydrazide TFA salt (359 mg, 1.05 mmol, 2.00 equiv.). The reaction mixture was stirred at room temperature for 16 hours. MTBE was added to the reaction mixture until a gum was formed and the solvent was decanted. To the gummy residue was added more MTBE and the mixture was incubated in an ultrasonic bath until the gum turned into a yellow solid. The solid was filtered and rinsed with MTBE to afford compound 15(126 mg, 29%, 93.2% pure); 1H NMR (500 MHz, DMF-d7) delta 10.50 (s, 0.4H), 10.42 (s, 0.6H), 8.95-8.44 (m, 4H), 7.92-7.88 (m, 4H), 7.03 (s, 0.8H), 7.02 (s, 1.2H), 3.62-3.35 (m, 6H), 2.46-2.33 (m, 5H), 1.98 (s, 3H), 1.78-1.50 (m, 8H), 1.43-1.22 (m, 4H); HPLC-MS 93.2%, m/z for C29H37N5011Pt [(M+H)+] = 828.3, 151038-94-7

The synthetic route of 151038-94-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; PLACON THERAPEUTICS, INC.; KADIYALA, Sudhakar; MOREAU, Benoit; BILODEAU, Mark T.; WHALEN, Kerry; SINGH, Sukhjeet; WOOSTER, Richard; LEMELIN, Charles-Andre; (151 pag.)WO2016/209935; (2016); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

151038-94-7, 6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanehydrazide 2,2,2-trifluoroacetate is a pyrrolines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

151038-94-7, Example 8. Preparation of Compound 19 [0281] [0282] The hydrazide-TFA salt of Compound 19-2 (6.4mg, 20 mumol) was added to a mixture of Compound 19-1 (7.7 mg, 10 mumol) in 5 methanol/dichloromethane at 0 . The reaction mixture was warmed to the ambient temperature and stirred for 5h, then concentrated under reduced pressure and purified on a silica gel column eluting with 3 methanol/dichloromethane to give 3.3 mg of Compound 19-3. MS [M+H] +: 973.42.

151038-94-7 6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanehydrazide 2,2,2-trifluoroacetate 23509306, apyrrolines compound, is more and more widely used in various fields.

Reference£º
Patent; BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD.; YUAN, Jiandong; SONG, Yunsong; HUANG, Yangqing; ZHU, Rui; HU, Xiaowei; FANG, Cheng; WO2015/106599; (2015); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

151038-94-7, 6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanehydrazide 2,2,2-trifluoroacetate is a pyrrolines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Acetoxycisplatin(4-acetylphenyl)carbamate (215 mg, 0.400 mmol, 1.0 equiv.) was dissolved in DMF (0.05M, 8 mL) and treated with 6-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l- yl)hexanehydrazide TFA salt (163 mg, 0.480 mmol, 1.2 equiv.) at room temprature. The reaction mixture was stirred at room temperature ovemight. Dichloromethane was added to the reaction mixture and the suspension was filtered to provide a yellow solid (230mg, 77% yield, 90.9% pure). The residue obtained was triturated with MeCN to provide compound 18 as a yellow solid (144 mg, 48% yield, 97.3% pure). NMR (500 MHz, DMF-d7) delta 10.28 (s, 0.4H), 10.15 (s, 0.6H), 9.74 (brs, 1H), 7.79-7.72 (m, 2H), 7.61-7.54 (m, 2H), 7.22-6.81 (m, 6H), 7.02 (s, 2H), 3.50-3.44 (m, 2H), 2.74-2.70 (m, 1.2H), 2.40- 2.35 ( m, 0.8H), 2.33 (s, 2H), 2.29 (s, 1H), 1.93 (s, 3H), 1.72-1.63 (m, 2H), 1.62-1.53 (m, 2H), 1.42-1.29 (m, 2H); HPLC-MS 97%, m/z for C2iH3oCl2N607Pt [(M+H)+] = 745.2., 151038-94-7

The synthetic route of 151038-94-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; PLACON THERAPEUTICS, INC.; KADIYALA, Sudhakar; MOREAU, Benoit; BILODEAU, Mark T.; WHALEN, Kerry; SINGH, Sukhjeet; WOOSTER, Richard; LEMELIN, Charles-Andre; (151 pag.)WO2016/209935; (2016); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.151038-94-7,6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanehydrazide 2,2,2-trifluoroacetate,as a common compound, the synthetic route is as follows.

A solution of 1,1?,2-trisnor-squalenic aldehyde (8) (0.334g, 0.868mmol) in CH2Cl2 was added to dry methanol (15mL). The resulting mixture was sonicated for a few minutes until complete dissolution. [6-(maleimido)hexanamido]azanium trifluoroacetate (7) [23] (0.306g, 0.868mmol) and 4A molecular sieves (200mg) were then added and the reaction mixture was stirred for 1h at room temperature under nitrogen. The formation of the desired product (9) was monitored by TLC (petroleum ether/ethyl acetate 1/1v/v, Rf: 0.65). The mixture was filtered and concentrated under reduced pressure. The residue was taken into water (5mL) and extracted with CH2Cl2 (3¡Á15mL). The combined organic phases were dried over anhydrous MgSO4 and concentrated in vacuo. Purification by flash-chromatography on silica column, eluting with a gradient of petroleum ether to petroleum ether/ethyl acetate 60/40v/v, gave the product as a light yellow waxy material (0.211g, 63% yield) (Supplementary material, Fig. S1). (0008) 1H NMR (CDCl3) delta: 8.39 (s, 1H, CH=NN), 7.05 (t, J=5.2Hz, 1H, NHCO), 6.68 (s, 2H, CO-CH=CHCO), 5.14-5.07 (m, 5H, HC=C(CH3)), 3.54-3.49 (t, J=7.2Hz, 2H, CH2N), 2.70-2.50 (m, 2H, CH2CONH), 2.40-1.90 (m, 20H, =C(CH3)CH2CH2), 1.80 (s, 3H, HC=C(CH3)2), 1.76-1.65 (m, 12H, HC=C(CH3)CH2), 1.62-1.60 (m, 4H, NCH2CH2CH2CH2CH2CON), 1.41-1.33 (m, 2H, NCH2CH2CH2CH2CH2CON). 13C NMR (CDCl3) delta: 171.2, 166.3, 147.3, 135.8, 135.7-132.0, 125.9-124.7, 42.5, 39.7-26.4, 38.2, 36.6, 31.0, 26.9, 25.9, 24.6-16.4, 22.4. MS (EI): m/z(%) 81 (70), 110 (100), 192 (55), 591 (3). HPLC analysis: Symmetry C18 column, 5mum (Merck, Italy) equipped with a C18 column guard, elution with 100% methanol, detection by UV adsorption measurement at 237nm (flow rate 1mL/min, tr=5.79min). Peak heights were recorded and processed on a CBM-10A Shimadzu interface.

151038-94-7, As the paragraph descriping shows that 151038-94-7 is playing an increasingly important role.

Reference£º
Article; Valetti, Sabrina; Mura, Simona; Desmale, Didier; Noiray, Magali; Vergnaud, Juliette; Vauthier, Christine; Couvreur, Patrick; Stella, Barbara; Cattel, Luigi; Giraudo, Enrico; Maione, Federica; Journal of Controlled Release; vol. 192; (2014); p. 29 – 39;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

151038-94-7, 6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanehydrazide 2,2,2-trifluoroacetate is a pyrrolines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

[00247] Acetoxyoxaliplatin(4-acetylphenyl)carbamate was first synthesized using acetoxy(hydroxyl)oxaliplatin (243 mg, 0.51 mmol, 1 .00 equiv) and 4- acetylphenylisocyanate (124 mg, 0.77 mmol, 1 .50 equiv) dissolved in DMF (0.1 M, 5 mL). The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated and impregnated on silica gel. The crude product was purified by normal phase chromatography using silica gel column (40 g) eluted with 5-20% MeOH / CH2CI2 gradient over 15 minutes. Pure fractions were combined and concentrated under vacuum to provide the product as a yellow solid (241 mg, 74%, 83% pure). HPLC-MS 83.1 %, m/z for CigHzsNsOgPt +H)+] = 635.2. 16 [00248] Synthesis of acetate 4-(1-(2-(6-(2,5-dioxo-2H-pyrrol-1(5H)- l)hexanoyl)hydrazono)ethyl) phenyl carbamate oxaliplatin: Acetoxyoxalplatin(4- acetylphenyl)carbamate (228 mg, 0.36 mmol, 1 .00 equiv) was dissolved in DMF (0.05 M, 7 mL) and treated with 6-(2,5-dioxo-2,5-dihydro-1 H-pyrrol-1 – yl)hexanehydrazide TFA salt (158 mg, 0.47 mmol, 1 .30 equiv). The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was concentrated and the residue was triturated with acetonitrile to precipitate the product as a yellow powder. This powder was triturated first with isopropyl alcohol (iPrOH) and then with DCM to afford the desired product (70 mg, 23%, 93.5% pure). HPLC-MS 93.5%, m/z for CzgHssNeOu Pt [(M+H)+] = 842.3. 1 H NMR (500 MHz, DMF-d7) 5 10.34-10.15 (m, 1 H), 9.91 -9.66 (m, 1 H), 9.37-9.24 (m, 1 H), 8.88-8.66 (m, 2H), 8.59-8.48 (m, 1 H), 7.80-7.73 (m, 2H), 7.61 -7.53 (m, 2H), 7.04-6.98 (m, 2H), 3.50-3.43 (m, 2H), 3.14-3.02 (m, 1 H), 2.75-2.70 (m, 1 H), 2.43-2.25 (m, 6H), 2.01 -1 .92 (m, 3H), 1 .74-1 .53 (m, 9H), 1 .42-1 .24 (m, 4H)., 151038-94-7

The synthetic route of 151038-94-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BLEND THERAPEUTICS, INC.; MOREAU, Benoit; BILODEAU, Mark T.; WHALEN, Kerry; MEETZE, Kristan; SINGH, Sukhjeet; WOOSTER, Richard; LEMELIN, Charles-Andre; (139 pag.)WO2015/200250; (2015); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.151038-94-7,6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanehydrazide 2,2,2-trifluoroacetate,as a common compound, the synthetic route is as follows.

Compound 3 (69.5 mg, 0.1 mmol) was dissolved in 20 mL of absolute ethanol. Then add 6-maleimidocaproyl hydrazide trifluoroacetate(6-maleimidocaprohydrazide trifluoroacetate salt) (101.8 mg,0.3 mmol) and 5.6 muL of trifluoroacetic acid (TFA).The reaction system was stirred at room temperature for 12 hours in the dark.After the reaction, the reaction system was diluted with methanol.Purification was carried out by HPLC.HPLC purification conditions were 5-95% acetonitrile for gradient elution.The elution flow rate was 25 mL/min.Purification afforded compound 4 (TCO-Dox-Mal).

151038-94-7, 151038-94-7 6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanehydrazide 2,2,2-trifluoroacetate 23509306, apyrrolines compound, is more and more widely used in various.

Reference£º
Patent; Peking University; Chen Peng; Lin Feng; (14 pag.)CN109939242; (2019); A;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem